| scholarly article | Q13442814 |
| P50 | author | Alan J Gelenberg | Q114443869 |
| David Kupfer | Q5236159 | ||
| Augustus John Rush | Q21104277 | ||
| Maurizio Fava | Q30089873 | ||
| Philip Ninan | Q42705984 | ||
| Madhukar Trivedi | Q87600331 | ||
| Michael E Thase | Q91359309 | ||
| Harold A Sackeim | Q104577740 | ||
| Jerrold F Rosenbaum | Q114238489 | ||
| Helena Chmura Kraemer | Q56677294 | ||
| P2093 | author name string | Alan F Schatzberg | |
| Ellen Frank | |||
| Darrel A Regier | |||
| Oakley Ray | |||
| ACNP Task Force | |||
| P2860 | cites work | The PHQ-9: validity of a brief depression severity measure | Q24550620 |
| A rating scale for depression | Q24564540 | ||
| Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis | Q24794437 | ||
| The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 | ||
| An Inventory for Measuring Depression | Q26778503 | ||
| A New Depression Scale Designed to be Sensitive to Change | Q29614720 | ||
| Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice | Q29614979 | ||
| Development of a Rating Scale for Primary Depressive Illness | Q29616244 | ||
| The number needed to treat: a clinically useful measure of treatment effect | Q29619672 | ||
| Outcome predictors for the cognitive behavior treatment of bulimia nervosa: data from a multisite study | Q30604391 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthre | Q31121202 | ||
| World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder | Q31121208 | ||
| Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors | Q32069179 | ||
| Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients | Q33857420 | ||
| Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology | Q33886704 | ||
| Time to recurrence after recovery from major depressive episodes and its predictors | Q33967302 | ||
| An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. | Q34090610 | ||
| Cost-effectiveness of systematic depression treatment for high utilizers of general medical care | Q34140444 | ||
| Effectiveness of electroconvulsive therapy in community settings | Q34292633 | ||
| Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design | Q34310720 | ||
| The development of study exit criteria for evaluating antimanic compounds. | Q34314954 | ||
| A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression | Q34315386 | ||
| Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial | Q34514200 | ||
| Sertraline versus imipramine to prevent relapse in chronic depression. | Q34516027 | ||
| A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. | Q34550854 | ||
| Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms | Q34661137 | ||
| The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. | Q34756072 | ||
| The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. | Q34756079 | ||
| Mediators and moderators of treatment effects in randomized clinical trials | Q34940844 | ||
| Residual symptoms in depression: an emerging therapeutic target | Q35009395 | ||
| Research issues in the study of difficult-to-treat depression | Q35111596 | ||
| The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach | Q35111772 | ||
| Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. | Q35142087 | ||
| Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. | Q39648029 | ||
| The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression | Q41323343 | ||
| 12-month outcome of patients with major depression and comorbid psychiatric or medical illness (compound depression). | Q42091498 | ||
| When should a trial of fluoxetine for major depression be declared failed? | Q42596035 | ||
| The impact of medical comorbidity on acute treatment in major depressive disorder. | Q42614034 | ||
| The Inventory of Depressive Symptomatology (IDS): psychometric properties. | Q42635264 | ||
| Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study | Q42666725 | ||
| The definition of remission and its impact on the length of a depressive episode | Q70706521 | ||
| Residual symptoms after partial remission: an important outcome in depression | Q71095565 | ||
| Early nonresponse to fluoxetine as a predictor of poor 8-week outcome | Q71776333 | ||
| Prevention of relapse in residual depression by cognitive therapy: a controlled trial | Q73716943 | ||
| A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities | Q73782396 | ||
| A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder | Q77567516 | ||
| Partial remission in major depression: a two-phase, 12-month prospective study | Q77703835 | ||
| Psychosocial predictors of outcome in major depression: a prospective 12-month study | Q77838305 | ||
| Implications of using different cut-offs on symptom severity scales to define remission from depression | Q80209672 | ||
| Which depressed patients respond to nefazodone and when? | Q43577325 | ||
| ECT in bipolar and unipolar depression: differences in speed of response | Q43595309 | ||
| Response and Remission Rates in Different Subpopulations With Major Depressive Disorder Administered Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Placebo | Q43844467 | ||
| Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination | Q43873740 | ||
| Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study | Q44742910 | ||
| Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. | Q44881365 | ||
| A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder | Q44922744 | ||
| Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine | Q44962398 | ||
| Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group | Q46068856 | ||
| A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. | Q46326672 | ||
| The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a | Q47198959 | ||
| Reliability of treadmill exercise testing in older patients with chronic hemiparetic stroke | Q47619268 | ||
| Defining guilt in depression: a comparison of subjects with major depression, chronic medical illness and healthy controls | Q51045361 | ||
| Outcome Definitions and Predictors in Depression | Q51095341 | ||
| Major depressive subtypes and treatment response | Q51101013 | ||
| Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features | Q51930117 | ||
| Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project | Q51939426 | ||
| Psychosocial disability before, during, and after a major depressive episode: a 3-wave population-based study of state, scar, and trait effects | Q51941888 | ||
| Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. | Q51988725 | ||
| Continuation drug therapy for major depressive episodes: how long should it be maintained? | Q52080861 | ||
| The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance | Q52112284 | ||
| Treatments of depression and the functional capacity to work | Q52478123 | ||
| Defining remission on the Montgomery-Asberg depression rating scale | Q53352978 | ||
| Addressing ethical issues in the psychiatric research literature | Q53544758 | ||
| Residual symptoms in depressed patients who respond acutely to fluoxetine | Q53933212 | ||
| Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment | Q53946367 | ||
| The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. | Q54326619 | ||
| Medication resistance and clinical response to electroconvulsive therapy. | Q54329990 | ||
| A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. | Q55033901 | ||
| Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. | Q55051636 | ||
| The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression | Q57616579 | ||
| Resistance to antidepressant medications and short-term clinical response to ECT | Q58958047 | ||
| Gepirone Extended-Release Treatment of Anxious Depression | Q59674910 | ||
| Assessment of reliability in the clinical evaluation of depressive symptoms among multiple investigators in a multicenter clinical trial | Q60447048 | ||
| A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy | Q60620332 | ||
| Speed of Response and Remission in Major Depressive Disorder With Acute Electroconvulsive Therapy (ECT) | Q61480078 | ||
| Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment | Q68220090 | ||
| Seizure threshold in electroconvulsive therapy. Effects of sex, age, electrode placement, and number of treatments | Q68982303 | ||
| Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy | Q70580672 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1841-1853 | |
| P577 | publication date | 2006-06-21 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Neuropsychopharmacology | Q2261280 |
| P1476 | title | Report by the ACNP Task Force on response and remission in major depressive disorder | |
| P478 | volume | 31 |
| Q34207131 | A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression |
| Q45916380 | A New Population-Enrichment Strategy to Improve Efficiency of Placebo-Controlled Clinical Trials of Antidepressant Drugs |
| Q35182015 | A Systematic Review of the Combined Use of Electroconvulsive Therapy and Psychotherapy for Depression |
| Q48290418 | A comparison of depressed patients in randomized versus nonrandomized trials of antidepressant medication and psychotherapy |
| Q37328704 | A computerized decision support system for depression in primary care |
| Q37168747 | A follow-up study of first episode major depressive disorder. Impairment in inhibition and semantic fluency-potential predictors for relapse? |
| Q35737324 | A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression |
| Q46904750 | A practical approach to the early identification of antidepressant medication non-responders. |
| Q51822922 | A psychometric evaluation of the clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-C16) in patients with bipolar disorder. |
| Q35671677 | A randomized clinical trial of a telephone depression intervention to reduce employee presenteeism and absenteeism |
| Q33782206 | A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned |
| Q96019147 | A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression |
| Q48544253 | A randomized-controlled trial of an intervention to improve antidepressant adherence among Latinos with depression |
| Q54984669 | A review of vagus nerve stimulation as a therapeutic intervention. |
| Q48156013 | ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression |
| Q36984391 | Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy |
| Q48425543 | Acute and chronic stress exposure predicts 1-year recurrence in adult outpatients with residual depression symptoms following response to treatment |
| Q37254739 | Addressing circadian rhythm disturbances in depressed patients |
| Q21144599 | Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes |
| Q38093228 | Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review |
| Q24617019 | Agomelatine: The evidence for its place in the treatment of depression |
| Q92626351 | Alterations of amplitude of low-frequency fluctuation in treatment-resistant versus non-treatment-resistant depression patients |
| Q36507081 | Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression |
| Q54966148 | Antidepressant drug-specific prediction of depression treatment outcomes from genetic and clinical variables. |
| Q48974584 | Antidepressant monotherapy and combination of antidepressants in the treatment of resistant depression in current clinical practice: A retrospective study |
| Q33683586 | Antidepressant pharmacotherapy in adults with type 2 diabetes: rates and predictors of initial response |
| Q39246637 | Are Patients with Childhood Onset of Insomnia and Depression More Difficult to Treat Than Are Those with Adult Onsets of These Disorders? A Report from the TRIAD Study |
| Q80376629 | Association of the COMT val158met variant with antidepressant treatment response in major depression |
| Q33812060 | Attachment and social adjustment: relationships to suicide attempt and major depressive episode in a prospective study |
| Q89956568 | Augmenting usual care SSRIs with cognitive behavioral therapy for insomnia to improve depression outcomes in youth: Design of a randomized controlled efficacy-effectiveness trial |
| Q44748636 | Baseline patient characteristics as predictors of remission in interpersonal psychotherapy for depression |
| Q38080645 | Blinding integrity in randomized sham-controlled trials of repetitive transcranial magnetic stimulation for major depression: a systematic review and meta-analysis |
| Q48856082 | Brain stimulation therapies for mood disorders: the continued necessity of electroconvulsive therapy |
| Q38947818 | Brexpiprazole. |
| Q36168261 | Broader conceptualization of remission assessed by the remission from depression questionnaire and its association with symptomatic remission: a prospective, multicenter, observational study |
| Q37609900 | Calibration of response and remission cut-points on the Beck Depression Inventory-Second Edition for monitoring seasonal affective disorder treatment outcomes |
| Q47837939 | Can depression in psychogeriatric inpatients at one year follow-up be explained by locus of control and coping strategies? |
| Q45951919 | Can integrating the Memory Support Intervention into cognitive therapy improve depression outcome? Study protocol for a randomized controlled trial. |
| Q37315816 | Change in psychosocial functioning and depressive symptoms during acute-phase cognitive therapy for depression |
| Q36325950 | Childhood neglect predicts the course of major depression in a tertiary care sample: a follow-up study. |
| Q58583073 | Choline and N-acetyl aspartate levels in the dorsolateral prefrontal cortex at the beginning of the recovery phase as markers of increased risk for depressive episode recurrence under different duration of maintenance therapy and after it: a retrospe |
| Q36160387 | Clinical correlates of complicated grief among individuals with acute coronary syndromes |
| Q92909426 | Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental |
| Q27027184 | Clinically Meaningful Efficacy and Acceptability of Low-Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Primary Major Depression: A Meta-Analysis of Randomized, Double-Blind and Sham-Controlled Trials |
| Q24646517 | Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia |
| Q37014626 | Collaborative depression care, screening, diagnosis and specificity of depression treatments in the primary care setting |
| Q35190797 | Comparison of cerebral blood flow in oral somatic delusion in patients with and without a history of depression: a comparative case series |
| Q89665749 | Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better |
| Q102328391 | Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report |
| Q37202637 | Continuation-phase cognitive therapy's effects on remission and recovery from depression |
| Q28764080 | Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults |
| Q47960923 | Cultural adaptation and validation of the Chinese version of the Fatigue Severity Scale in patients with major depressive disorder and nondepressive people |
| Q37091883 | Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview |
| Q33632801 | DHA serum levels were significantly higher in celiac disease patients compared to healthy controls and were unrelated to depression. |
| Q37712388 | Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder |
| Q38283390 | Defining 'recovery' for delirium research: a systematic review. |
| Q37713660 | Defining and measuring functional recovery from depression |
| Q33691346 | Defining recovery from an eating disorder: Conceptualization, validation, and examination of psychosocial functioning and psychiatric comorbidity |
| Q50785904 | Defining response and remission in psychotherapy research: A comparison of the RCI and the method of percent improvement |
| Q36795521 | Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods |
| Q37352035 | Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence |
| Q37585473 | Detecting critical decision points in psychotherapy and psychotherapy + medication for chronic depression |
| Q45055871 | Determining severity subtypes of depression with a self-report questionnaire |
| Q33900246 | Developing Cognitive Behavioral Therapy to Prevent Depressive Relapse in Youth |
| Q36585273 | Developing the evidence for evidence-based practice |
| Q37500406 | Development and validation of the Individual Burden of Illness Index for Major Depressive Disorder (IBI-D). |
| Q92617419 | Differences in Perceptions of Major Depressive Disorder Symptoms and Treatment Priorities Between Patients and Health Care Providers Across the Acute, Post-Acute, and Remission Phases of Depression |
| Q43945669 | Differential effects of early life stress on hippocampus and amygdala volume as a function of emotional abilities. |
| Q36752062 | Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study |
| Q37202188 | Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials |
| Q64226418 | Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression |
| Q47578748 | ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis. |
| Q40177894 | EMOTIONAL AVAILABILITY IN MOTHER-CHILD INTERACTION: THE EFFECTS OF MATERNAL DEPRESSION IN REMISSION AND ADDITIONAL HISTORY OF CHILDHOOD ABUSE. |
| Q38831504 | Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial |
| Q33655082 | Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder |
| Q92703447 | Economic burden of relapse/recurrence in patients with major depressive disorder |
| Q53825912 | Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. |
| Q33955258 | Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency |
| Q34324317 | Efficacy and acceptability of high frequency repetitive transcranial magnetic stimulation (rTMS) versus electroconvulsive therapy (ECT) for major depression: a systematic review and meta-analysis of randomized trials |
| Q52807350 | Efficacy and moderators of psychological interventions in treating subclinical symptoms of depression and preventing major depressive disorder onsets: protocol for an individual patient data meta-analysis of randomised controlled trials. |
| Q42638301 | Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors |
| Q37398383 | Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies |
| Q43042829 | Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders |
| Q26828452 | Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis |
| Q35930407 | Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy |
| Q63112394 | Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review |
| Q33900047 | Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial |
| Q37410419 | Enhanced visual motion perception in major depressive disorder. |
| Q35038925 | Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial |
| Q92897481 | Evidence-Based Applications of Combination Psychotherapy and Pharmacotherapy for Depression |
| Q36960404 | Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone |
| Q57073841 | Five Interpersonal Factors Are Predictive of the Response to Treatment of Major Depression With Antidepressants in Primary Care |
| Q33667966 | Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. |
| Q53104699 | French Society for Biological Psychiatry and Neuropsychopharmacology and Fondation FondaMental task force: Formal Consensus for the management of treatment-resistant depression |
| Q38756244 | Friendship, Depression, and Suicide Attempts in Adults: Exploratory Analysis of a Longitudinal Follow-Up Study |
| Q47815343 | Functional connectivity of the left DLPFC to striatum predicts treatment response of depression to TMS. |
| Q48456170 | Further evidence that the cutoff to define remission on the 17-item Hamilton Depression Rating Scale should be lowered |
| Q48335550 | Health-related quality of life in recurrent major depressive disorder—A 10-year follow-up study |
| Q30408079 | How emotional abilities modulate the influence of early life stress on hippocampal functioning. |
| Q43954959 | How should residual symptoms be defined in depressed patients who have remitted? |
| Q38203227 | Hypothalamic-pituitary-adrenocortical axis: neuropsychiatric aspects |
| Q36537329 | Impact of Reproductive Status and Age on Response of Depressed Women to Cognitive Therapy |
| Q90076942 | Implementation of intermittent theta burst stimulation compared to conventional repetitive transcranial magnetic stimulation in patients with treatment resistant depression: A cost analysis |
| Q36244847 | Improved cognitive content endures for 2 years among unstable responders to acute-phase cognitive therapy for recurrent major depressive disorder |
| Q41438172 | Improving outcome for mental disorders by enhancing memory for treatment |
| Q35549797 | Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression |
| Q37670602 | Influences on antidepressant prescribing trends in the UK: 1995-2011. |
| Q34465439 | Internet-based treatment of major depression for patients on a waiting list for inpatient psychotherapy: protocol for a multi-centre randomised controlled trial |
| Q38246365 | Interventions for preventing relapse or recurrence of depression in primary health care settings: A systematic review |
| Q57526903 | Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report |
| Q38696595 | Is treatment-resistant depression a useful concept? |
| Q57074526 | Low hedonic tone and attention-deficit hyperactivity disorder: risk factors for treatment resistance in depressed adults |
| Q89846120 | Lower Choline-Containing Metabolites/Creatine (Cr) Rise and Failure to Sustain NAA/Cr Levels in the Dorsolateral Prefrontal Cortex Are Associated with Depressive Episode Recurrence under Maintenance Therapy: A Proton Magnetic Resonance Spectroscopy |
| Q35284412 | Major depressive disorder: mechanism-based prescribing for personalized medicine |
| Q38036472 | Managing Depression for Residents in Nursing Facilities |
| Q37475271 | Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice |
| Q84969845 | Measurement-based care for unipolar depression |
| Q38950555 | Memory support strategies and bundles: A pathway to improving cognitive therapy for depression? |
| Q91622024 | Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients |
| Q91329907 | MicroRNA mediators of early life stress vulnerability to depression and suicidal behavior |
| Q36616883 | Mindfulness meditation and cognitive behavioral therapy for insomnia: a naturalistic 12-month follow-up |
| Q45911121 | Modeling the Risks and Benefits of Depression Treatment for Children and Young Adults |
| Q33857182 | Moderators of continuation phase cognitive therapy's effects on relapse, recurrence, remission, and recovery from depression |
| Q30355089 | Music in depression: Neural correlates of emotional experience in remitted depression |
| Q34498865 | Natural course of cannabis use disorders |
| Q37178455 | Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects |
| Q40314455 | No impact of eight NTRK2 genetic polymorphisms on 6-month antidepressant efficacy in depressed patients. |
| Q24602982 | Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). |
| Q48297249 | Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: A 52-week follow-up study |
| Q47828475 | Operating characteristics of PROMIS four-item depression and anxiety scales in primary care patients with chronic pain. |
| Q37144258 | Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment |
| Q44878577 | Partial remission indicates poor functioning and a high level of psychiatric symptoms: a 3-phase 6-year follow-up study on major depression |
| Q34603620 | Partial remission, residual symptoms, and relapse in depression |
| Q46771639 | Patient learning of treatment contents in cognitive therapy. |
| Q38617459 | Patient recall of specific cognitive therapy contents predicts adherence and outcome in adults with major depressive disorder |
| Q24170133 | Personalized medicine in major depressive disorder -- opportunities and pitfalls |
| Q43592185 | Pharmacoepigenetics of depression: no major influence of MAO-A DNA methylation on treatment response. |
| Q34090827 | Pharmacogenetics of antidepressive treatment |
| Q33730306 | Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial |
| Q90224430 | Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication |
| Q38011436 | Pharmacology and neuroimaging of antidepressant action |
| Q34548227 | Pioglitazone could induce remission in major depression: a meta-analysis |
| Q95306981 | Pre-treatment allostatic load and metabolic dysregulation predict SSRI response in major depressive disorder: a preliminary report |
| Q64067030 | Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials |
| Q82759405 | Prediction of response to antidepressants: is quantitative EEG (QEEG) an alternative? |
| Q39713514 | Predictors of Incidence, Remission and Relapse of Axis I Mental Disorders in Young Women: A Transdiagnostic Approach |
| Q92509516 | Predictors of depression relapse and recurrence after cognitive behavioural therapy: a systematic review and meta-analysis |
| Q35626207 | Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder |
| Q34378212 | Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo |
| Q37037502 | Prevention of depression: the state of the science at the beginning of the 21st Century |
| Q36835344 | Profiles of Recovery from Mood and Anxiety Disorders: A Person-Centered Exploration of People's Engagement in Self-Management |
| Q36392646 | Proof of concept: Partner-Assisted Interpersonal Psychotherapy for perinatal depression |
| Q46781246 | Psychological Distress Severity of Adults Reporting Receipt of Treatment for Mental Health Problems in the BRFSS |
| Q34664030 | RETRACTED: Effect of cognitive therapy with antidepressant medications vs antidepressants alone on the rate of recovery in major depressive disorder: a randomized clinical trial |
| Q35598795 | RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response |
| Q47555291 | Re-evaluation of the definition of remission on the 17-item Hamilton Depression Rating Scale based on recovery in health-related quality of life in an observational post-marketing study |
| Q46454654 | Recent Advances in Non-invasive Brain Stimulation for Major Depressive Disorder |
| Q92375607 | Recognition of personality disorder and anxiety disorder comorbidity in patients treated for depression in secondary psychiatric care |
| Q36914727 | Recovery and subsequent recurrence in patients with recurrent major depressive disorder |
| Q47107468 | Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study |
| Q48259957 | Recurrence risk in major depression |
| Q37070494 | Reducing relapse and recurrence in unipolar depression: a comparative meta-analysis of cognitive-behavioral therapy's effects |
| Q33745342 | Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes |
| Q34626301 | Remission in major depression: results from a geriatric primary care population |
| Q64102776 | Repetitive Transcranial Magnetic Stimulation in Youth With Treatment Resistant Major Depression |
| Q46002104 | Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. |
| Q34333771 | Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials |
| Q37776074 | Review: The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission |
| Q37442874 | Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial |
| Q57171785 | Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis |
| Q45931500 | STAR*D: revising conventional wisdom. |
| Q35236999 | Sadness as an integral part of depression |
| Q58781967 | Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety |
| Q34626306 | Sensitivity to change and predictive validity of the MOODS-SR questionnaire, last-month version. |
| Q48324504 | Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response |
| Q89672137 | Sexual functioning in females with depression in remission receiving escitalopram |
| Q47140935 | Significant Need for a French Network of Expert Centers Enabling a Better Characterization and Management of Treatment-Resistant Depression (Fondation FondaMental). |
| Q42618250 | Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial |
| Q34572593 | Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder |
| Q37229333 | Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales |
| Q47864124 | Stem Cell Factor (SCF) is a putative biomarker of antidepressant response |
| Q37289129 | Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms |
| Q40045551 | Sustained effectiveness and cost-effectiveness of the Healthy Activity Programme, a brief psychological treatment for depression delivered by lay counsellors in primary care: 12-month follow-up of a randomised controlled trial. |
| Q84158980 | Switch antidepressants: when? How? Why? |
| Q42665301 | Switching to duloxetine from selective serotonin reuptake inhibitors in non- or partial responders: Results from a Spanish sample. |
| Q48611989 | Symptom differences between depressed outpatients who are in remission according to the Hamilton Depression Rating Scale who do and do not consider themselves to be in remission |
| Q34315319 | Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder |
| Q48245078 | Symptom profiles of DSM-IV-defined remission, recovery, relapse, and recurrence of depression: the role of the core symptoms |
| Q45333645 | Targeting remission by 8 weeks: when should supplementation be considered in patients with major depression treated with a specific serotonin reuptake inhibitor? |
| Q37957770 | Targeting treatment-resistant depression |
| Q37294169 | Ten ways to improve the treatment of depression and anxiety in adults |
| Q36069882 | The Bypassing the Blues treatment protocol: stepped collaborative care for treating post-CABG depression |
| Q26752694 | The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder |
| Q33664080 | The Impact of Residual Symptoms in Major Depression |
| Q64257695 | The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs |
| Q34741960 | The STAR*D Project results: a comprehensive review of findings. |
| Q36299404 | The association between subjective memory complaint and objective cognitive function in older people with previous major depression |
| Q37141494 | The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder |
| Q35737847 | The course of depression in late life as measured by the Montgomery and Asberg Depression Rating Scale in an observational study of hospitalized patients |
| Q27692061 | The depression treatment cascade in primary care: a public health perspective |
| Q92088397 | The network structure of core depressive symptom-domains in major depressive disorder following antidepressant treatment: a randomized clinical trial |
| Q100760582 | The olfactory deficits of depressed patients are restored after remission with venlafaxine treatment |
| Q92625122 | The process and delivery of CBT for depression in adults: a systematic review and network meta-analysis |
| Q36607589 | The prognostic significance of subsyndromal symptoms emerging after remission of late-life depression |
| Q41411632 | The responsiveness of the different versions of the Hamilton Depression Scale |
| Q37777008 | Therapeutic Armamentarium for Treating Depression |
| Q38246286 | Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine |
| Q35142665 | Toward an online cognitive and emotional battery to predict treatment remission in depression |
| Q35237032 | Towards achieving remission in the treatment of depression |
| Q35244135 | Treating Post-CABG Depression With Telephone-Delivered Collaborative Care: Does Patient Age Affect Treatment and Outcome? |
| Q48955752 | Treating depression and achieving remission |
| Q37275966 | Use of antidepressants in late-life depression |
| Q30490331 | Using daily monitoring of psychiatric symptoms to evaluate hospital length of stay |
| Q37334485 | Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model |
| Q39353790 | Vagal Nerve Stimulation for Treatment-Resistant Depression |
| Q53691732 | Vagus Nerve Stimulation (VNS) and Other Augmentation Strategies for Therapy-Resistant Depression (TRD): Review of the Evidence and Clinical Advice for Use. |
| Q31061376 | Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antide |
| Q39245331 | Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. |
| Q36538439 | What Are the Implications of the STAR*D Trial for Primary Care? A Review and Synthesis |
| Q95588626 | What factors indicate prognosis for adults with depression in primary care? A protocol for meta-analyses of individual patient data using the Dep-GP database |
| Q40073042 | What predicts attrition in second step medication treatments for depression?: a STAR*D Report. |
| Q48402157 | Why do some depressed outpatients who are not in remission according to the hamilton depression rating scale nonetheless consider themselves to be in remission? |
Search more.